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Abstract
Multiple sclerosis, the most common cause of neurological disability in young population
after trauma, represents a significant public health burden. Current challenges associated
with management of multiple sclerosis (MS) patients stem from the lack of biomarkers that
might enable stratification of the different clinical forms of MS and thus prompt treatment for
those patients with progressive MS, for whom there is currently no therapy available. In the
present work we analyzed a set of thirty different plasma cytokines, chemokines and growth
factors present in circulation of 129 MS patients with different clinical forms (relapsing remit-
ting, secondary progressive and primary progressive MS) and 53 healthy controls, across
two independent cohorts. The set of plasma analytes was quantified with Luminex xMAP
technology and their predictive power regarding clinical outcome was evaluated both individ-
ually using ROC curves and in combination using logistic regression analysis. Our results
from two independent cohorts of MS patients demonstrate that the divergent clinical and his-
tology-based MS forms are associated with distinct profiles of circulating plasma protein bio-
markers, with distinct signatures being composed of chemokines and growth/angiogenic
factors. With this work, we propose that an evaluation of a set of 4 circulating biomarkers
(HGF, Eotaxin/CCL11, EGF and MIP-1β/CCL4) in MS patients might serve as an effective
tool in the diagnosis and more personalized therapeutic targeting of MS patients.
Introduction
Multiple sclerosis (MS), the most common cause of neurological disability in young population
after trauma, represents a significant personal, social and economic public health burden. MS
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is a chronic autoimmune inflammatory disorder of the central nervous system (CNS) charac-
terized by multiple demyelination lesions, axonal degeneration and oligodendrocyte and neu-
ronal loss. The precise etiology of MS remains unknown, although it is widely held that MS is a
Th1/Th17 autoimmune disease, where self-reactive effector T cells initiate the inflammatory
cascade. The clinical course of MS goes from an early inflammatory phase of the disease with
relapses and remissions, where patients may respond to immunomodulatory drugs, to a pro-
gressive and neurodegenerative phase that is unresponsive to any currently available treatment.
Between 60–70% of patients with a relapsing-remitting MS (RR-MS) form evolve to a second-
ary-progressive form of MS (SP-MS). About 20% of patients suffer from a progressive onset of
the disease without remissions of infaust prognosis, known as primary progressive MS
(PP-MS) [1]. In either case, it remains plausible that the various clinical MS forms may repre-
sent divergent etiologies, given the distinct pathological patterns and the clinical characteristics
they exhibit. Although CNS magnetic resonance imaging (MRI) and the presence of oligoclo-
nal bands in the cerebrospinal fluid (CSF) have helped in the diagnosis of MS, they do not dis-
criminate between the inflammatory and progressive forms at MS.
Many cytokines and their receptors have been predominantly detected in MS lesions and
they are thought to play a role in MS pathogenesis via immune system activation as well as via
damaging neuronal cells. Proinflammatory cytokines have been extensively studied. CSF levels
of proinflammatory cytokines are often elevated in MS patients [2–8].
The current challenges in the management of MS patients are linked to the lack of biomark-
ers capable of stratifying the different clinical forms of MS. This is a high priority due to the
need to define those patients that may evolve to progressive forms. Indeed, the development of
minimally invasive biomarkers represents an important avenue for discriminating among the
different forms of the disease and for predicting treatment response. They can also help to shed
light on MS pathogenesis.
In our cohort of MS patients, we evaluated plasma profiles of cytokines, chemokines and
growth factors both individually using ROC curves and in combination using logistic regres-
sion analysis for their predictive power regarding the clinical outcome. We have found a set of
potential biomarkers differently expressed in the relapsing-remitting MS patients compared to
MS patients in the progressive phase of the disease that might serve as an effective tool for strat-
ifying MS patients and better target personalized therapies for this complex disease.
Materials and Methods
Subjects
A total of 182 subjects were studied in this work. Among them, 129 patients with definite MS
diagnosis according to McDonald’s criteria [9] were consecutively recruited from November
2010 to June 2012, at the Unit of Multiple Sclerosis of the University General Hospital Gregorio
Marañón and from Center Alicia Koplowitz for Multiple Sclerosis of the Community of Ma-
drid, Spain. A group of 53 age-matched healthy controls (HC) (29 women/24 men; age: 37
years (31–43) median value (IQR1-3)) from the Blood Donor Bank of the University Hospital
Gregorio Marañón was also included. Patients were considered and analyzed as two indepen-
dent cohorts: the test cohort (cohort 1) was recruited from November 2010 to February 2011
and consisted of 65 MS patients (47 women and 18 men) and 16 HC (9 women and 7 men);
the validation cohort (cohort 2) was recruited from June 2011 to June 2012 and consisted of 64
MS patients (38 women and 26 men) and 37 HC (20 women and 17 men).
MS patients were characterized into two main groups, as “inflammatory MS or RR-MS” and
“progressive MS”. The “inflammatory MS/ RR-MS” group consisted of patients diagnosed as
Relapsing-Remitting form that were in the inflammatory phase of the disease and was
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composed of the following subgroups: Recurrent-Remitting MS patients in remission (RR-MS
Remission), RR-MS patients with active disease (RR-MS Active), patients at clinical exacerba-
tion or relapse (RELAPSES), RR-MS patients under treatment with IFN-β for a minimum of 6
months who had a good clinical response to IFN-β and were defined as long-term IFN-β re-
sponders (RESPONDERS), RR-MS patients that had not responded to IFN-β (NON-RE-
SPONDERS) and were going to start other disease-modifying therapy (DMT). The
“progressive MS” group included patients diagnosed as Secondary-Progressive MS (SP-MS) or
Primary-Progressive MS (PP-MS). Except for the long-term IFN-β RESPONDERS group, the
rest of the patients had not received any glucocorticoid treatment, immunosuppressive or
DMT before blood sampling in the three months prior to study entry. The different groups are
depicted in Table 1. In the group of RR-MS Remission, there were 17 benign forms of MS that
had been symptom-free for years. A patient with RR-MS with active disease (RR-MS Active)
was defined as a patient with clinical and paraclinical activity of the disease, that was studied at
least 1 month after the end of a clinical exacerbation and was eligible to start a DMT. Relapse
was defined as the appearance or reappearance of one or more neurological abnormalities that
persisted for at least 24 h and which had been preceded by at least 30 days of stable or improved
neurological state, without any underlying infectious disease; blood samples were drawn from
Table 1. Epidemiological and clinical characteristics of multiple sclerosis patients included in the study.
Inflammatory MS/ RR-MS Progressive MS
Characteristics CD-MS RR-MS
Remission
RR-MS
Active
RELAPSES RESPONDERS NON
RESPONDERS
SP-MS PP-MS
No. of patientsa 129 23 13 11 20 13 31 18
Gender F/Ma 85/44 17/6 8/5 8/3 10/10 11/2 22/9 9/9
Age (years)b 42 (33–53) 38 (32–46) 29 (26–37) 30 (26–42) 37 (33–41) 38 (29–43) 53 (46–
58)
58 (45–64)
Disease duration
(yrs)b
11 (3–
17.5)
9 (5–16) 1 (1–4.5) 1 (0–9) 9 (1.8–16.3) 11 (5–15.5) 19 (13–
27)
20.5 (8.8–
26.3)
Age at onset (yrs)b 28 (24–36) 28 (22–32) 26 (25–35) 28 (25–40) 26 (23–35) 26 (24–38) 32 (26–
41)
40 (33–50)
EDSSb 2.5 (1.0–
5.5)
0.0 (0.0–1.5) 2.5 (1.0–
3.0)
3.0 (2.0–
4.0)
1.0 (0.0–2.0) 3.5 (2.3–4.5) 8.0 (7.5–
8.5)
8.0 (7.3–
8.0)
Progression Indexc 0.3 (0.1–
0.6)
0.0 (0.0–0.1) 1.5 (0.2–
2.9)
0.8 (0.2–
5.4)
0.1 (0.0–0.3) 0.3 (0.2–0.5) 0.4 (0.3–
0.6)
0.4 (0.3–
0.9)
No. of relapsesd
0 73 17 0 6 2 0 30 18
1 18 4 3 3 4 3 1 0
2–5 38 2 10 2 14 10 0 0
Treatment, IFNβa 20 _ _ _ 20 _ _ _
Treatment duration
(mo)b
18 (6–24) _ _ _ 18 (6–24) _ _ _
CD-MS clinically definite MS group, RR-MS Remission: relapsing remitting MS in remission, RR-MS Active: relapsing remitting MS with active disease,
RESPONDERS: RR-MS under treatment with IFNβ, NON-RESPONDERS: relapsing remitting MS that did not respond to Interferon-β, SP-MS: secondary
progressive MS, PP-MS: primary progressive MS.
EDSS expanded disability status scale, IFNβ: interferon-β.
a Number of patients;
b Median (25th-75th percentiles)
c EDSS/Disease duration (years);
d Number of relapses during preceding 2 years.
doi:10.1371/journal.pone.0128952.t001
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relapse patients before initiation of glucocorticoid treatment. Clinical disease severity and dis-
ability was rated according to the Kurtzke Expanded Disability Status Scale (EDSS) [10]. For
detailed patient characteristics, see Table 1. This study was approved by University Hospital
Gregorio Marañón Ethics Committee in Madrid and all subjects enrolled in the study gave
written informed consent.
Multiplexed biomarkers detection
Peripheral blood samples were taken by venous puncture and collected in sterile EDTA Vacu-
tainers, between 8:00 and 10:00 a.m., they were processed immediately or within 2 hours after
extraction. Plasma samples were obtained after high speed centrifugation for 10 minutes at
3,500–4,000 rpm and immediately aliquoted and frozen at -80°C for its conservation.
Plasma samples were clarified by high-speed centrifugation and analyzed using Luminex
xMAP technology platform. The current investigation required the assembly of an extensive
multiplex array consisting of cytokines, chemokines, soluble receptors, growth and angiogenic
factors, which were evaluated using bead-based immunoassays. The selected array was the
Human cytokine 30-Plex panel (Invitrogen) with the following analytes: IL-1β, IL-1RA, IL-2,
IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, TNF-α, IFN-α, IFN-γ,
GM-CSF, MIP-1α, MIP-1β/CCL4, IP-10, MIG, Eotaxin/CCL11, Rantes/CCL5, MCP-1/CCL2,
VEGF, G-CSF, EGF, FGF-basic, and HGF.
Statistical analysis
Descriptive data are presented as mean ± standard deviation (SD) and median (interquartile
range). We compared categorical by the chi-square χ2 test. When multiple groups with contin-
uous outcomes were compared, the nonparametric Kruskal-Wallis rank sum test was used, fol-
lowed by pairwise Mann-Whitney tests if the former indicated significant differences.
Correlations were assessed using Spearman correlation (rs) coefficients. Receiver operating
characteristic (ROC) curves were used to select the optimal cut-off values of significant vari-
ables for considering negative or positive predictors of the development of any given clinical
condition studied. Logistic regression and the area under the receiver operating curves
(AUROC) were used to determine the diagnostic accuracy of a model that included biomarkers
able to discriminate between patients and healthy controls. Data were analyzed with SPSS (Chi-
cago, Illinois) and GraphPad Prism software (CA, USA). A p-value less than 0.05 was consid-
ered as statistically significant. The Bonferroni correction was applied to compensate the
multiplicity of the tests.
Results
Demographic and clinical characteristics of MS patients
In our MS study population, 80 out of 129 (62%) MS patients were classified in the inflamma-
tory phase of the disease and were diagnosed as relapsing-remitting MS: RR-MS Remission
n = 26, RR-MS Active n = 13, RESPONDERS n = 20, NON RESPONDERS n = 13 and RE-
LAPSES n = 11 (for 6 out of 11 it was their first clinical episode (CIS), and they were later diag-
nosed as RR-MS). There were 49 patients in the progressive phase of the disease, 31 were
diagnosed as SP-MS and 18 as PP-MS.
RR-MS patients and patients at relapse had similar ages, while progressive patients SP-MS
and PP-MS were around 20 years older (Table 1). The lowest disease duration (median 1 year)
was in the groups of RR-MS with active disease and patients at relapse. In RR-MS at remission
and responders and non-responders to IFNβ, mean disease duration was about a decade and in
Plasma Biomarkers in the Different Clinical Forms of MS
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the progressive forms (SP-MS and PP-MS) two decades. SP-MS and PP-MS had the highest
EDSS compared to the other groups. EDSS in RR-MS Remission and in IFNβ RESPONDERS
were the lowest (median, 0 and 1, respectively), as expected. The progression index (EDSS/Dis-
ease duration (years) was the highest in RR-MS Active patients, as they had been recently diag-
nosed and presented with considerable disability. As depicted in Table 1, the patients with
highest number of relapses in the preceding two years where those under treatment with IFNβ
(RESPONDERS) or about to start therapy with a DMT (RR-MS Active and NON
RESPONDERS).
Panel of Plasma Biomarkers that Discriminate between Relapsing-
Remitting and Progressive Clinical Forms of Multiple Sclerosis
We proceeded from the hypothesis that biomarkers present in the circulation of patients diag-
nosed with different clinical forms of MS can provide clinically relevant information pertaining
to the progression of the disease and also a basis for the discrimination between the three con-
ditions (RR-MS, SP-MS and PP-MS). The evaluation of this hypothesis was conducted accord-
ing to the following objectives: firstly, biomarkers levels present in the plasma of several
distinct clinical forms of MS were examined in order to identify alterations associated with spe-
cific disease forms. Secondly, we focused on the use of a combination of biomarkers using lo-
gistic regression for their predictive power achieving superior sensitivity and specificity.
Given the intrinsic heterogeneity of MS, the two cohorts were pooled to increase the number
of cases and controls. With all the MS patients globally considered, the 30 analytes were tested
as predictors for the discrimination between Relapsing-Remitting and Progressive Clinical
forms of MS by ROC curves. For six of them (HGF, Eotaxin/CCL11, MCP-1/CCL2, Rantes/
CCL5, EGF and MIP-1β/CCL4) a p-Value< 0.05 was found, which in all six cases was
also< 0.05/30 (Table 2). Hence these results are still significant even when applying the Bon-
ferroni correction to the significance threshold, the most conservative method to compensate
the multiplicity of the tests.
HGF, Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 are present in
lower concentrations in the plasma of Relapsing-Remitting than in
Progressive Multiple Sclerosis patients
The analytes HGF, Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 were present at signifi-
cantly lower circulating levels in the RR-MS patients than in the progressive clinical forms of
MS patients (SP-MS and PP-MS).
The analysis of the test cohort revealed that HGF, Eotaxin/CCL11, MCP-1/CCL2, Rantes/
CCL5 were present in significantly lower concentrations in the inflammatory (RR-MS) phase
Table 2. Biomarkers that discriminate between Relapsing-Remitting and Progressive Clinical forms of MS by ROC curves.
RR-MS vs Progressive MS AUC (95% CI) p value Cut off (pg/ml)
HGF 0.702 (0.604–0.799) <0.0002 387
Eotaxin/CCL11 0.755 (0.662–0.849) <0.0001 132
MCP-1/CCL2 0.721 (0.626–0.816) <0.0001 550
Rantes/CCL5 0.792 (0.707–0.876) <0.0001 5536
EGF 0.689 (0.592–0.786) 0.0005 66
MIP-1β/CCL4 0.702 (0.607–0.798) <0.0002 109
The areas under the curve (AUC), 95% Confidence Interval (95% CI) and p value for each analyte are depicted in Table 2.
doi:10.1371/journal.pone.0128952.t002
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with respect to the progressive MS clinical forms (SP-MS and PP-MS), findings that were con-
firmed in the validation cohort (Table 3). HGF, Eotaxin/CCL11 and Rantes/CCL5 differences
between these two groups were statistically significant in both cohorts analyzed independently
(Table 3). Plasma MCP-1/CCL2 levels in RR-MS patients showed a trend to be lower in the
test cohort (p = 0.06), while in the validation cohort, this difference was statistically significant
(p = 0.0002).
The two cohorts were pooled to increase the number of cases and controls. Again, in MS pa-
tients globally considered, we found that plasma levels of HGF, Eotaxin/CCL11, MCP-1/CCL2
and Rantes/CCL5 were significantly lower in the inflammatory (RR-MS patients) than in the
progressive forms (SP-MS and PP-MS). In Fig 1 the results from RR-MS are compared to those
of the progressive MS patients: (HGF: 294±221 vs 484±310, p = 0.0002; Eotaxin/CCL11: 87±56
vs 187±143, p<0.0001; MCP-1/CCL2: 375±227 vs 588±309, p<0.0001; Rantes/CCL5: 4,173
±4,855 vs 11,371±8,800, p<0.0001). Interestingly, the levels of HGF, MCP-1/CCL2 and
Eotaxin/CCL11 in the progressive MS patients were similar to those observed in healthy con-
trols (HGF: 484±310 vs 476±652; Eotaxin/CCL11: 187±143 vs 147±138; MCP-1/CCL2: 588
±309 vs 538±315), while Rantes/CCL5 was more elevated in the progressive forms with respect
to healthy controls (Rantes/CCL5: 11,371±8,800 vs 5,518±6,796). RR-MS patients had signifi-
cantly lower levels of Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 than healthy controls
(Eotaxin/CCL11: 87±56 vs 147±138, p = 0.001, MCP-1/CCL2: 375±227 vs 538±315, p = 0.001
and Rantes/CCL5: 4,173±4,855 vs 5,518±6,796, p = 0.0002).
Table 3. HGF, Eotaxin/CCL11, MCP-1/CCL2, Rantes/CCL5, EGF andMIP-1β/CCL4 comparison in the
test and validation cohorts.
RR-MS Progressive MS
Test cohort
HGF [pg/mL] 117 (67–351)** 406 (188–508)
Eotaxin/CCL11 [pg/mL] 69 (44–99)** 119±65
MCP-1/CCL2 [pg/mL] 325 (265–519)# 447 (337–561)
Rantes/CCL5 [pg/mL] 2,359 (1,105–6,066)*** 7,791 (5,548–7,791)
EGF [pg/mL] 55 (8–89)*** 8 (8–8)
MIP-1β/CCL4 [pg/mL] 135 (88–183)*** 51 (37–93)
Validation cohort
HGF [pg/mL] 334 (239–430)** 536 (344–805)
Eotaxin/CCL11 [pg/mL] 88 (60–122)*** 230 (121–381)
MCP-1/CCL2 [pg/mL] 357 (205–461)*** 680 (391–1,005)
Rantes/CCL5 [pg/mL] 2,641 (1,649–4,841)*** 23,644 (4,029–23,644)
EGF [pg/mL] 106 (63–155)# 64 (46–106)
MIP-1β/CCL4 [pg/mL] 131 (95–189)# 94 (79–129)
Mann—Whitney statistical test was used for calculation of the reported p-value between RR-MS vs
Progressive MS; RR-MS = Relapsing-Remitting MS patients. Note that the Relapsing-remitting group
comprises the clinical groups: RR-MS Remission, RR-MS Active, RESPONDERS, NON RESPONDERS
and RELAPSES. The Progressive group comprises Secondary (SP-MS) and Primary-progressive patients.
Results are given as Median value (IQR1–3). Statistical significance is marked as:
*p<0.05;
**p<0.01;
***p<0.001.
# p = 0.06 (trend).
doi:10.1371/journal.pone.0128952.t003
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The ROC analyses indicated a good performance of plasma HGF, Eotaxin/CCL11, MCP-1/
CCL2 and Rantes/CCL5 for the discrimination between RR-MS from progressive clinical
forms (Table 2).
HGF correlated strongly with MCP-1/CCL2 both in MS patients and in healthy controls (rs
= 0.4674, p<0.0001), whilst HGF correlated with Eotaxin/CCL11 (rs = 0.5574, p<0.0001) and
Rantes/CCL5 (rs = 0.3317, p = 0.0002) only in MS patients.
HGF, MCP-1/CCL2, Eotaxin/CCL11 and Rantes/CCL5 correlated also with neurological
disability measured by the EDSS: HGF (rs = 0.3254, p = 0.0003), MCP-1/CCL2 (rs = 0.2714,
p = 0.003), Eotaxin/CCL11 (rs = 0.3610, p<0.0001), Rantes/CCL5 (rs = 0.4386, p<0.0001).
EGF and MIP-1β/CCL4 are diminished in Progressive MS clinical forms
Both in the test cohort and in the validation cohort, EGF and MIP-1β/CCL4 plasma levels were
lower in the progressive MS forms (SP-MS and PP-MS) with respect to RR-MS patients. In the
test cohort, plasma EGF and MIP-1β/CCL4 statistically differed in both classification groups
Fig 1. Different plasma levels of HGF, Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 in MS clinical forms. Plasma levels of HGF, Eotaxin/CCL11,
MCP-1/CCL2 and Rantes/CCL5 were lower in relapsing-remitting MS than in the progressive MS patients. Comparison of the plasma levels of HGF, Eotaxin/
CCL11 (top dot plots), MCP-1/CCL2 and Rantes/CCL5 (lower dot plots) in relapsing-remitting (RR-MS, n = 80) and in the group of progressive MS (n = 49)
patients. Mann—Whitney statistical test was used for calculation of the reported p-value; median values are represented by a gray bar; individual dots
indicate single donor values. Note that the Relapsing-remitting group comprises the clinical groups: RR-MS Remission, RR-MS Active, RESPONDERS,
NON RESPONDERS and RELAPSES. The Progressive group comprises Secondary (SP-MS) and Primary-progressive patients.
doi:10.1371/journal.pone.0128952.g001
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(p<0.0001 and p = 0.0002, respectively); in the validation cohort, both analytes showed a trend
(p = 0.06) to be at lower concentrations in the plasma of progressive patients (SP-MS and
PP-MS) than in RR-MS patients (Table 3).
The pool of both cohorts displayed the same distribution with significantly diminished cir-
culating levels of EGF and of the chemokine MIP-1β/CCL4 in patients with progressive forms
of MS than in RR-MS patients (EGF: 87±71 vs 50±54, p = 0.0005; MIP-1β/CCL4: 141±79 vs 93
±67, p = 0.0002) (Fig 2). RR-MS patients and healthy controls showed similar circulating levels
of EGF and MIP-1β/CCL4 (EGF: 87±71 vs 115±92; MIP-1β/CCL4: 141±79 vs 170±116) and
progressive patients had significantly lower levels of EGF and MIP-1β/CLL4 than HC (EGF: 50
±54 vs 115±92, p<0.0001 and MIP-1β/CCL4: 93±67 vs 170±116, p = 0.0002, respectively). The
ROC curves of plasma EGF and MIP-1β/CCL4 were used to assess the potential identification
between RR-MS and progressive (SP-MS or PP-MS) clinical forms (Table 2).
As expected, EGF and MIP-1β/CCL4 correlated negatively with the disability score EDSS:
EGF (rs = -0.2906, p<0.002, MIP-1β/CCL4 (rs = -0.355, p<0.0001).
Logistic regression
We carried out the multivariate logistic regression analysis including all these six analytes
(HGF, MCP-1/CCL2, Eotaxin/CCL11, Rantes/CCL5, EGF and MIP-1β/CCL4) as independent
variables and the clinical MS-forms (Relapsing-Remitting vs Progressive) as the dichotomous
target variable. We obtained a model that included the 4 analytes HGF, EGF, Eotaxin/CCL11
and MIP-1 β/CCL4) (Table 4) as predictors for the MS-clinical form, while Rantes/CCL5 and
MCP-1/CCL2 did not reach statistical significance to be included.
With this combination model, we were able to give the odds for a specific patient to be diag-
nosed as progressive MS, i.e. the probability—P—of being classified as progressive clinical form
of MS divided by the probability of developing a relapsing-remitting form 1-P, according to the
model are given by the product of 0.4021 and the four odds ratios each raised by the respective
predictors’ values (in pg/mL) measured in an individual patient. Each analyte has an odds ratio
(O.R.) which is raised to the power of its respective value [pg/mL] in a patient. For instance, for
a patient with values [pg/mL] of Eotaxin/CCL11: 200; HGF: 323; EGF: 17; MIP-1β/CCL4: 54,
Fig 2. Different plasma levels of EGF and MIP-1β/CCL4 in MS clinical forms. Plasma levels of EGF and MIP-1β/CCL4 were lower in the progressive MS
than in relapsing-remitting MS patients. Comparison of the plasma levels of EGF and MIP-1β/CCL4 between patients with relapsing-remitting (RR-MS,
n = 80) and in progressive MS patients (n = 49). Mann—Whitney statistical test was used for calculation of the reported p-value; median values are
represented by a gray bar; individual dots indicate single donor values. Note that the Relapsing-remitting group comprises the clinical groups: RR-MS
Remission, RR-MS Active, RESPONDERS, NON RESPONDERS and RELAPSES. The Progressive group comprises Secondary (SP-MS) and Primary-
progressive patients.
doi:10.1371/journal.pone.0128952.g002
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the odds are 0.4021  1.0147200  1.0038323  0.980817  0.987354 = 9.14. Hence, the model assigns
to this patient a probability of having a progressive form of 9.14 / (1+9.14) = 90.1%.
HGF and Eotaxin/CCL11 with O.R.>1 (Table 4) are risk factors for developing a progres-
sive clinical form of MS, while EGF and MIP-1β/CCL4 with O.R.<1 are protective factors for
developing a progressive clinical form of MS.
Considering odds>/< 1, i.e. a greater/less probability of having a progressive versus
RR-MS clinical form according to the model, as a positive/negative prognosis, the model gives
a sensitivity of 71.7%, a specificity of 89.9%, a positive predictive value (PPV) of 82.5%, a nega-
tive predictive value of 82.7% and an accuracy of 82.6% for our cohort of MS patients.
Each of the analytes included in the combination model by multivariate logistic regression
analysis was independently analyzed by univariate regression analysis (ROC Analysis) for its
predictive ability to discriminate between a Progressive and a RR-MS patient. For each ana-
lyte, an specific cut-off value: HGF>387, Eotaxin/CCL11>132, EGF<66 and MIP-1β/CCL4
<109 pg/ml could discriminate with different sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and accuracy between a Progressive and a RR-MS pa-
tient. The combination of the four plasma levels of HGF, Eotaxin/CCL11, EGF and MIP-1β/
CCL4 with multivariate logistic regression analyses gave a higher sensitivity and specificity
(Table 5).
FGFb can discriminate between Primary and Secondary Progressive
patients and between Primary Progressive patients and Relapsing-
Remitting patients undergoing clinical relapse
Plasma FGFb was markedly diminished in PP-MS patients when compared to SP-MS (11±10
vs 26±27, p = 0.01), patients undergoing a clinical relapse (11±10 vs 21±11, p = 0.01), or
Table 4. Logistic regression with HGF, Eotaxin/CCL11, EGF and MIP-1β/CCL4 as independent vari-
ables and the clinical MS-forms (Relapsing-Remitting vs Progressive MS) as the dichotomous target
variable.
RR-MS vs Progressive MS P value O.R. C.I. (95%)
HGF [pg/mL] 0.0085 1.0038 1.0010–1.0066
Eotaxin/CCL11 [pg/mL] 0.0004 1.0147 1.0066–1.0229
EGF [pg/mL] 0.0056 0.9808 0.9675–0.9944
MIP-1β/CCL4 [pg/mL] 0.0171 0.9873 0.9769–0.9977
Constant 0.1049 0.4021
O.R. (odds ratio); C.I. (95%) Interval of confidence.
doi:10.1371/journal.pone.0128952.t004
Table 5. Clinical utility of HGF, Eotaxin/CCL11, EGF andMIP-1β/CCL4 as MS biomarkers and clinical utlity of their combination in a model by multi-
variate logistic regression analysis.
RR-MS vs Progressive MS Sensitivity Specificity PPV NPV Accuracy
HGF 59.6% 72.6% 58.3% 73.6% 67.5%
Eotaxin/CCL11 53.2% 90.8% 78.1% 75.8% 76.4%
EGF 74.5% 59.7% 54.7% 78.2% 65.5%
MIP-1β/CCL4 70.2% 68.4% 57.9% 78.8% 69.1%
Model by logistic regression analysis 71.7% 89.9% 82.5% 82.7% 82.6%
PPV: positive predictive value, NPV: negative predictive value.
doi:10.1371/journal.pone.0128952.t005
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healthy controls (11±10 vs 28±31, p = 0.02) (Fig 3). This distinction is important because MS
at onset can be divided into two main forms: relapsing-remitting and primary progressive.
VEGF Levels were higher in Secondary Progressive than in Relapsing-
Remitting MS
Patients with SP-MS had significantly higher circulating levels of the vascular epidermal
growth factor (VEGF) than all the patients with RR-MS (32±28 vs 15±9, p = 0.0004) and than
healthy controls (32±28 vs 21±11, p = 0.04) (Fig 4). Patients with PP-MS had also lower circu-
lating levels of VEGF than SP-MS, but this difference was not statistically significant.
IP10, MCP-1/CCL2 circulating levels are significantly higher in
Relapsing-Remitting patients that respond to IFN-β treatment than in
Non Responders
Among the chemokines tested, IP10/CXCL10 and MCP-1/CCL2 were significantly higher in
RR-MS patients under treatment with IFN-β (RESPONDERS) than in those patients who had
been previously treated with IFN-β and did not respond to therapy and had clinical activity
(NON RESPONDERS) (IP10: 111±60 vs 96±136, p = 0.04; MCP-1/CCL2: 446±158 vs 272
±152, p = 0.008) (Fig 5). These two cytokines are induced by type I IFN, but only IP10/
CXCL10 levels were significantly higher in the RESPONDERS group when compared to the
levels of the group of HC (111±60 vs 86±86, p = 0.005) and to those levels of the rest of RR-MS
patients without treatment (RR-MS Remission, RR-MS Active, RELAPSES and NON RE-
SPONDERS) (111±60 vs 75±78, p = 0.0003). IP10 levels were also higher in the progressive
forms of MS (SP-MS and PP-MS) than in the rest of RR-MS patients without treatment stud-
ied: In PP-MS patients, there was a modest increase (96±75 vs 75±78, p = 0.05), whereas in
SP-MS patients these differences were more remarkable (102±52 vs 75±78, p = 0.0001). SP-MS
had also higher circulating levels of IP10 than the group of healthy controls (102±52 vs 86±86,
p = 0.01).
Fig 3. FGFb levels were significantly decreased in primary progressive MS patients.Comparison of the
plasma levels of FGFb between primary progressive MS patients (PP-MS, n = 18) with respect to healthy
controls (HC, n = 36), to secondary progressive MS patients (SP-MS, n = 31) and to patients undergoing a
clinical relapse (RELAPSES, n = 11). Mann—Whitney statistical test was used for calculation of the reported
p-value; median values are represented by a gray bar; individual dots indicate single donor values.
doi:10.1371/journal.pone.0128952.g003
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The combinations of biomarkers were simultaneously down or up-regulated in the individ-
uals. In Fig 6, the different concentrations of the biomarkers in each clinical form of Multiple
Sclerosis patients RR-MS, SP-MS and PP-MS are represented.
Discussion
In MS, cytokines have been thoroughly studied, but the role of chemokines and even more of
growth factors in the pathogenesis of the disease remains to be elucidated. Studies analyzing
Fig 4. VEGF levels were significantly higher in secondary progressive MS patients. Plasma levels of
the vascular growth factor (VEGF) in the validation cohort, were higher in secondary progressive MS patients
(SP-MS, n = 16) than in patients with the relapsing-remitting form (RR-MS, n = 38) and than in healthy
controls (HC, n = 20). The SP-MS patients had higher plasma levels of VEGF than primary progressive MS
patients (PP-MS, n = 9) but this difference did not reach statistical significance. Mann—Whitney statistical
test was used for calculation of the reported p-value; median values are represented by a gray bar; individual
dots indicate single donor values.
doi:10.1371/journal.pone.0128952.g004
Fig 5. IP10/CXCL10 and MCP-1/CCL2 levels were higher in MS patients with good response to IFN-β treatment. Long-term IFN-β treated RR-MS
patients (RESPONDERS, n = 20) presented with higher circulating levels of IP10/CXCL10 and MCP-1/CCL2 than non responders to IFN-β (NON
RESPONDERS, n = 13). Mann—Whitney statistical test was used for calculation of the reported p-value; median values are represented by a gray bar;
individual dots indicate single donor values.
doi:10.1371/journal.pone.0128952.g005
Plasma Biomarkers in the Different Clinical Forms of MS
PLOSONE | DOI:10.1371/journal.pone.0128952 June 3, 2015 11 / 21
comprehensive cytokines, chemokines and growth factors profiles in a large cohort of patients
with MS are lacking. Here we attempt to identify relevant circulating cytokines, chemokines
and growth factors associated with the diverse pathophysiological pathways that encompass
MS through the comparison of a broad array of plasma biomarkers in patients with distinct
clinical forms of MS.
To the best of our knowledge, we are the first to describe significant differences in circulating
levels of FGFb, HGF, VEGF; Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 discriminating
among MS clinical forms. The biomarker analysis described herein provides a revealing cross-
section of the pathophysiological MS conditions. Despite recent advances in disease-modifying
therapies and biologicals for MS, current treatment regimens remain characterized by disap-
pointment due to a failure to stop progression in PP-MS and potentially life-threatening adverse
effects. There is an urge need to recognize and predict outcome in the individual MS patient
that could enable more focused treatment strategies. Therefore, the identification and develop-
ment of targeted therapies has moved to the forefront of the MS translational research.
Chemokines and their receptors have an important role in the pathophysiology of MS given
the organ-specific nature of MS. They can act as chemoattractants through the recruitment of
autoreactive cells from the periphery to the CNS and induce the secretion of proinflammatory
cytokines, which promote the final demyelination and neuronal loss [11, 12]. CXCL10/IP-10,
Fig 6. Plasma biomarkers regulations in our MS clinical forms. The combinations of biomarkers were
down or up-regulated simultaneously in the individuals. The results are represented with a box and whiskers
graph. The bottom and top of the box represent the first and third quartiles, the median values are
represented by the line inside the box and the ends of the whiskers represent the minimum and maximum of
the values. Biomarkers from Relapsing-remitting MS patients are represented with an R, secondary-
progressive MS patients are represented with and S and primary-progressive MS patients are represented
with a P. Note that the Relapsing-remitting group comprises the clinical groups: RR-MS Remission, RR-MS
Active, RESPONDERS, NONRESPONDERS and RELAPSES.
doi:10.1371/journal.pone.0128952.g006
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CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/Rantes, CCL7/MCP-3 and CXCL9/Mig
[11–25] are among the described proinflammatory chemokines produced by immune cells and
CNS glia in MS and in the animal model of MS, experimental autoimmune encephalomyelitis
(EAE). Most of the β-chemokines or CC chemokine ligands (CCL) genes are clustered in chro-
mosome 17q11.2–12, a location that has been associated with MS in different studies [26–28].
In a model of EAE, increased levels of Eotaxin/CCL11 were associated with milder disease phe-
notype, tighter blood brain barrier, reduced antigenic specific response and an anti-inflamma-
tory Th2 phenotype [29].
In addition, different growth factors have relevance in the CNS disorders. The hepatocyte
growth factor (HGF) is a multifunctional protein in the CNS that is produced by microglial
cells, oligodendroglial progenitor cells, astrocytes and neurons [30–33]. The receptor for HGF,
c-Met, is the tyrosine kinase product of the c-Met proto-oncogene [34, 35] and both HGF and
its receptor c-Met are present during brain development and persist in adulthood with impor-
tant neurotrophic functions [36, 37]. Besides, peripheral HGF shows immunomodulatory ef-
fects: promoting the adhesion of B cells [38], migration of T cells [39] and recruitment of
dendritic cells (DCs) [40, 41]. HGF has been found to be increased in CNS diseases, including
MS and in prototypic neurodegenerative diseases, such as Alzheimer’s disease [42]. However,
other studies have found decreased HGF CSF levels in patients with MS [43, 44] or unaltered
levels of plasmatic HGF between MS patients and healthy controls [44]. The epidermal growth
factor (EGF) has positive effects in the proliferation and differentiation of neurons, astrocytes
and oligodendrocytes [45, 46] and its co-administration with growth hormone (GH) in EAE
improved the clinical score and survival rate of mild and severe EAE forms [47]. In MS pa-
tients, EGF in CSF has been found to be significantly lower than in other non-inflammatory
neurological diseases [48]. Also, the basic fibroblast growth factor (FGFb or FGF-2), is a key
regulator of the growth, differentiation, migration and survival of CNS glial progenitors [45],
and its expression is enhanced in active MS lesions [49]. FGFb has a controversial role in MS.
It has been associated with demyelination and inhibition of myelin production by oligodendro-
cytes in vivo [50, 51] while with the induction of myelination in oligodendrocytes in vitro [52].
Recently, the knockout mouse of FGFb revealed rather a neuroprotective role for this growth
factor in the animal model of MS [53].
Here we show that a low expression of FGFb/FGF-2 is a selective marker of PP-MS, proba-
bly reflecting low remyelination related to progressive neurodegeneration. FGFb is an emerging
MS biomarker with a controversial role in promoting myelination by oligodendrocytes [50–
52], since the knockout mouse of FGFb in EAE showed that this growth factor has a neuropro-
tective/regenerative role avoiding nerve fiber degeneration and axonal loss and favoring remye-
lination in the CNS [53]. In MS, FGFb has been found to be increased in the CSF and serum of
MS patients, with the highest levels in clinically active MS patients undergoing relapse and in
SP patients with disability progression [54]. FGFb is a main mitogen of oligodendrocyte pre-
cursor cells (OPCs), mainly expressed at MS periplaques where macrophagic and/or activated
microglial and perivascular astrocyte-related remyelination, further supporting its role in neu-
rorepair and neuroprotection, respectively, as well as in maintaining the integrity of the blood-
brain barrier [49]. In our cohort of MS patients, we found that patients with PP-MS had signifi-
cantly low levels of FGFb. In contrast, clinically active patients with SP-MS and patients at re-
lapse showed similar levels to those of healthy controls. This finding is in agreement with the
study by Sarchielli et al. who reported an elevation of FGFb in the CSF of MS patients, and the
highest levels at relapse and in SP-MS patients with a recent increase in disability [54]. FGFb
might be playing a compensatory role during the inflammatory attack and during the axonal
insult that occurs at these stages of the disease. The fact that PP-MS patients had marked lower
FGFb circulating levels may be pointing to an impaired production with respect to other MS
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clinical forms, suggesting an additional defect in PP-MS to restore myelination and explain
their rapid disability progression compared to other patients. FGFb could be used as a future
therapeutic target to induce effective migration of MS lesions by OPCs and to favor remyelina-
tion of lesions.
In our cohort of MS patients, the SP-MS form was characterized by overexpression of the
vascular endothelial growth factor (VEGF) with respect to RR-MS and even to PP-MS patients.
VEGF is a prominent player in the complex and highly regulated process of angiogenesis and a
proinflammatory factor [55–58] suggesting its role in the RR-MS to the SP-MS transition. An
increase of VEGF-A in the initial phases of relapse is compatible with its role as a pro-inflam-
matory factor that attracts monocytes and lymphocytes, upregulates immunomodulatory ad-
hesion molecules, stimulates secretion of proinflammatory cytokines, and increases blood-
brain barrier permeability [59, 60]. Evidence for the occurrence of neovascularization in MS
has been observed by contrast-enhanced MRI in the appearance of “ring enhancement” at the
periphery, but not at the center of chronic lesions [61] Another MRI study showed a direct cor-
relation between serum VEGF levels and the magnitude of spinal cord lesions, suggesting that
VEGF might be involved in the formation of MS spinal cord lesions [62]. Increased levels of
VEGF and its receptor VEGFR-1 are found in astrocytes in MS plaques during the inflammato-
ry phase [63, 64]. In addition, intrastriatal injection of VEGF aggravates plaque inflammation
at the site of injection [64]. Moreover, as VEGF expression is highly influenced by inflammato-
ry cytokines and ischemia (see below), the accumulation of VEGF may be not only a mediator
but the result of MS inflammation. While all these findings may suggest that VEGF, as a factor
affecting vessels or inflammatory cells, aggravates MS, VEGF, as a neuroprotective factor, can
also protect against axonal damage in MS. Thus the precise role of VEGF in MS remains enig-
matic. Possibly, VEGF exerts a dual role in MS lesions: increased levels of VEGF can amplify
vascular permeability in vessels and thus inflammation through glial cells during the acute
phase of the disease, but can also stimulate the proliferation of neurons and their axons during
the chronic phases of the disease [60]. Recent evidence described low RNA VEGF levels in CSF
and blood PBMCs of SP-MS patients with respect to RR-MS [65].
By our logistic regression model combining four relevant biomarkers (HGF, Eotaxin/
CCL11, EGF and MIP-1β/CCL4), there was a significant overall model fit discriminating a di-
chotomous RR-MS versus progressive forms, with a specificity of 89.9% and a negative and pos-
itive predictive value of 82.7% and 82.5%, respectively. In our cohort of patients, having normal
(similar to HC) plasma HGF and Eotaxin/CCL11 levels and low plasma EGF and MIP-1β/
CCL4 levels were prognostic risk factors for being classified as a progressive patient with MS
(SP-MS or PP-MS). The levels of HGF, MCP-1/CCL2 and Eotaxin/CCL11 were higher in
SP-MS and PP-MS patients than in RR-MS, but similar to those observed in healthy controls.
Therefore, at the RR-MS stage of the disease, circulating levels of the β-chemokines MCP-1/
CCL2, Eotaxin/CCL11 and of the growth factor HGF, were diminished with respect to other
MS clinical forms and to healthy controls, suggesting a potential role for these diminished mole-
cules in the initial stages of MS pathogenesis. MCP-1/CCL2 levels have been reported to be de-
creased in MS patients [11, 66–69] although its expression in MS lesions is increased [28].
MCP-1/CCL2 stimulates in vitro the production of HGF by a mouse macrophage cell line [70]
and in vivo Müller et al. reported that low levels of MCP-1/CCL2 correlated strongly with low
levels of HGF at the central compartment [44]. We have found that plasma levels of the β-che-
mokines: MCP-1/CCL2, Rantes/CCL5 and Eotaxin/CCL11 correlate strongly with plasma levels
of HGF in MS, suggesting a physiopathological link between HGF and these β-chemokines.
The levels of Rantes/CCL5 were markedly elevated in the progressive forms with respect to
healthy controls and to RR-MS patients. Thus, high circulating levels of Rantes/CCL5 might be
reflecting a more progressive and disabling disease course. Rantes/CCL5 and its receptor CCR1,
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CCR3 and CCR5 have been detected in active demyelinating plaques on immune and microglia
cells [71, 72], its expression in serum is higher in RR-MS patients with active lesions and clinical
activity [68, 73, 74] and its concentration decreases in CSF after corticosteroid therapy [75].
Moreover, circulating T lymphocytes of progressive MS patients express higher expression of
the Rantes/CCL5 receptor CCR5 than those from healthy controls and show an increased mi-
gration towards Mip-1α/CCL3 and Rantes/CCL5 with a skewed Th1 phenotype [76, 77].
In addition, the levels of HGF, MCP-1/CCL2, Eotaxin/CCL11 and Rantes/CCL5 that were
all overexpressed in progressive MS patients correlated strongly with EDSS, the classical indica-
tor of clinical disability in MS, while EGF and MIP-1β/CCL4 that were diminished in progres-
sive patients inversely correlated with EDSS.
On the other hand, we found that the plasma levels of EGF and of the β-chemokine MIP-
1β/CCL4 were lower in SP-MS and PP-MS clinical forms with respect to RR-MS patients and
to healthy controls. Scalabrino et al. found lower levels of CSF EGF in RR-MS and SP-MS pa-
tients with respect to other non-inflammatory neurological diseases, but they found no differ-
ences in serum EGF among MS clinical forms [48], in this study the sample size was very
limited. In the present study, we do have found significantly diminished plasma EGF levels in
progressive MS patients than in RR-MS and than in healthy controls. MIP-1β/CCL4 shares the
same chemokine receptor, CCR5, with Rantes/CCL5 and with MIP-1α/CCL3. The target cells
of MIP-1β/CCL4 are CD8+ T lymphocytes and it has been detected in actively demyelinating
plaques where it is expressed by macrophages and microglia [12, 62].
The high degree of biological heterogeneity that characterizes MS, wherein the deregulated
inflammatory and neurodegenerative pathways vary, has hindered the clinical impact of tar-
geted therapies and emphasizes the need for improved tools aimed at identifying those patients
most likely to benefit from a particular treatment.
IP10/CXCL10 and MCP-1/CCL2 have previously been reported to be at higher levels in pa-
tients under treatment with IFN-β [78–81] and have been proposed as biomarkers for IFN-β
response [79, 80]. In this work, we observed that long term treatment with IFN-β translates
into persistent IP10 plasma levels in these patients, with values significantly higher than those
found in healthy controls and in the rest of groups with RR-MS, including RR-MS patients that
had not previously responded to IFN-β therapy. In addition, we observed that MCP-1/CCL2
discriminated between responder and non responder patients to IFN-β therapy. Moreover, we
observed that SP-MS patients had significantly higher circulating levels of IP10 than patients in
a RR-MS stage (excluding those patients with RR-MS but under therapy with IFN-β) and than
healthy controls. IP10 is a chemokine expressed by astrocytes that is upregulated and highly ex-
pressed in active demyelinating lesions [12, 66]. This chemokine has been found at increased
levels in serum and in the CSF of MS patients during exacerbations [66]. However, in our co-
hort of patients we did not observe higher plasma levels of IP10 in MS patients at relapse. Inter-
estingly, we remarked that progressive patients, especially SP-MS had increased circulating
levels of IP10. Several studies have reported increased endogenous production of IFN-γ by acti-
vated T lymphocytes expressing CCR5 from progressive MS patients [82, 83]. As IP10 is in-
duced by IFN, a high endogenous production of the Th1 cytokine, IFN-γ, by Th1 CCR5+
lymphocytes might be reflecting a positive endogenous loop of IP10 production.
This investigation illustrates the unique and informative role of plasma profiling in advanc-
ing our understanding of diverse pathophysiological pathways underlying the different MS
clinical forms and response to treatments. The plasma biomarkers significant across MS clini-
cal forms are summarized in Fig 7. There are scarce studies on the spatial and temporal differ-
ential expression of the chemokine system in the clinical forms of MS. The fact that among a
combination of 30 human cytokines, chemokines and growth factors; different plasma expres-
sion among clinical groups was only evident for chemokines and growth factors, underlines
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the importance of these proteins in the clinical course and pathophysiology of an organ-specif-
ic autoimmune disease, such as MS. Autoreactive immune cells have a CNS tropism and mi-
grate to their target organ, attracted by chemokines either through direct chemoattraction or
by the activation of their leukocyte integrins [84, 85]. Growth factors have outstanding rele-
vance peripherally and also in the central compartment, where they can participate in neovas-
cularization and remyelination to counteract the inflammatory attacks. Our findings suggest
that factors involved in the chemokine inflammatory response and growth/angiogenic factors
may differentially account for divergent MS clinical course. It is crucial that ongoing work in
the field of non-invasive biomarkers will be aimed at pinpointing the origins and functional
roles of the identified biomarkers, which could also allow more focused application of different
therapies. Continued investigation into the relationships between these factors should reveal
new insights into the complex mechanisms underlying MS pathophysiology.
We carried out an evaluation of circulating biomarkers in order to identify specific biomark-
ers and combinations of them which might serve as effective tools in the diagnosis and thera-
peutic targeting of MS patients. The biomarkers and their combinations found in this work
might be a useful diagnostic tool for a more accurate classification of MS clinical forms and
thus prompt treatment for those patients with progressive MS, for whom there is currently no
therapy available.
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